You are here: Industry Insights > Biogen

News List

Evaluating Risk: Gilead Sciences, Biogen and Celgene biospace
April 08, 2018
When it comes to large-cap biotech companies, Gilead Sciences, Biogen and Celgene are always worth investment consideration, but are not without their risks.
Biogen acquires Schizophrenia investigational drug candidate form Pfizer biospectrumasia
March 16, 2018
The purchase will include an upfront payment of $75 million with up to $515 million in additional development and commercialization milestone payments
Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Me biospace
March 16, 2018
Biogen (Nasdaq: BIIB) Italy (March 15-18, 2018). AAT-AD/PD is a new joint meeting between the International Geneva/Springfield Symposium on Advances in Alzheimer’s Therapy and AD/PD™.
Biogen to acquire first-in-class Phase IIb ready asset for cognitive impairment cphi-online
March 14, 2018
PF-04958242 is an AMPA receptor potentiator designed to facilitate neurotransmission.
Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associate biospace
March 13, 2018
Biogen Inc. (Nasdaq: BIIB) announced today an agreement to acquire from Pfizer Inc. (
Biogen Buys Pfizer's PhII-ready Schizophrenia Asset biospace
March 13, 2018
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
Biogen and AbbVie Voluntarily Pull Multiple Sclerosis Drug Off the Market biospace
March 05, 2018
Biogen and AbbVie have voluntarily pulled their Zinbryta for relapsing multiple sclerosis (MS) off the market after safety concerns.
Study Shows Biogen’s MS drug Tecfidera could make cancer-killing viruses more potent fiercebiotech
January 26, 2018
The Cancer-killing“oncolytic” viruses, which was derived from herpes, made their way into oncology practices in 2015 with Amgen’s melanoma drug Imlygic being approved.
Pfizer's Biosimilar of Biogen, Roche's Rituxan Meets Main Goal in Study biospace
January 25, 2018
Pfizer today announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera®(rituximab-EU), met its primary endpoint. PF-05280586 is being developed by Pfizer as a potential biosimilar to Rituxan®/MabThera®1.
Biogen to Report Fourth Quarter and Year-End 2017 Financial Results on January 25, 2018 biospace
December 22, 2017
Biogen (NASDAQ:BIIB) today announced it will report fourth quarter and year-end 2017 financial results on Thursday, January 25, 2018, before the financial markets open.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page